Solutions

Historically scientists have had to spend a significant amount of their limited resources (eg. animal housing, equipment, technical staff) with often inconsistent results. AccelBio delivers consistently superior, quality controlled and assured primary cells at the exact time needed at a fraction of the cost required. We are changing the way scientists and clinicians do their work by simplifying and accelerating research projects, freeing up time and budgets for other important discoveries.

Our proprietary cryopreservation techniques and applications result in greater performance compared to freshly isolated cells, affording a level of quality control that is unparalleled in the practice. Currently we are delivering primary neurons, glia, and other cell types including hepatocytes and induced pluripotent stem cells (iPSCs), and we would be delighted to take on the delivery of a new cell type or animal strain for long term customers, and to provide individualized service for projects.

CRYOPRESERVED CELLS: Our goal is to provide superior cells to the world's top scientists in efforts to accelerate discoveries in human disease, including neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's and motor neuron disease, as well as immunological disorders like AML and Hodgkins.

HIGH THROUGHPUT SCREENING: Using the highest quality primary cells from a preferred animal or stem cell model, AccelBio provides upstream and downstream solutions for companies and institutes on the leading edge of pharmacological, genetic, and chemical screens. Using our advanced platform, we offer high quality drug libraries with preferred chemical partners to help our clients focus on specific discovery pathways and rapidly advance their program. With our preferred genomic sequencing and analytic partners derived from the Broad Institute at MIT, our clients benefit from the most advanced research resources available currently.

TRANSGENIC CELL PROVIDERS: Our transgenic provider program gives researchers the scientific and logistical advantage of receiving cryopreserved cells for any cell type that they need from their own transgenic animals. Here at AccelBio we house and maintain the breeding program for investigators, and provide timed dissections and cryopreserved cells for their use when they need the material. Our expert husbandry program combined with our proprietary preservation technology means that we can provide clinicians and scientists with superior cellular products and unprecedented service that allows them to focus on discovery.

REGENERATIVE MEDICINE: Our focus on cell and genetic technologies has led our team to provide superior stem cells derived from customer sources for several regenerative medicine breakthroughs. We are pioneering several applications in metabolic and neurodegenerative diseases for cGMP and cGCP production of cells for transplantation and emerging gene therapy programs. This work is in collaboration with world leaders in CDMO production of cGCP material for human clinical trials. This program implements new methodologies that fosters preservation of trans-differentiated cell states after specific gene pathway induction, differentiation or transgenic applications. We are currently working with several leading biopharmaceutical corporations in this application.

COLD CHAIN OF CUSTODY: We provide the highest level of chain of custody around cryopreserved cells for research and clinical applications such as those used during surgery for regenerative medicine. Our barcoded vials, implemented with proprietary RF-ID and temperature monitor readout logistical solutions, enable a global shipping and receiving platform for the most demanding clients and clinical development applications. We work with global cryologistic partners to deliver our products with custom services and without delays.

Our products offer the following solutions:

  • less staff time devoted to cell harvesting logistics
  • no more unhealthy cells, only consistently perfect cultures
  • substantially lower cost than in-house production (see below)
  • increased productivity with no lag time to experiments
  • superior morphology and health, yielding better scientific results
  • no animal exposure for researchers with allergies
  • maintained cellular states for sensitive or difficult trans-differentiated cells 

Custom Services for Clients

shRNA and CRISPR Transduction Technology

We provide custom services that are in-house prepared using our acquired expertise that our clients have benefitted from for years. Our service includes custom shRNA construct preparation targeting any gene of interest. 

shRNA constructs are comprised of several options for client choice:

  • selection markers (fluorescent GFP or other color, antibiotic resistance)
  • inducible or constitutive promoter (U6 or H1)
Percentage knockdown of 36 shRNA constructs targeting 6 genes (including control). On average >70% of our designed constructs transduce at a 70% or greater expression and transcript knockdown as determined by Q-PCR.

Percentage knockdown of 36 shRNA constructs targeting 6 genes (including control). On average >70% of our designed constructs transduce at a 70% or greater expression and transcript knockdown as determined by Q-PCR.

We provide several services for construct design. We will design your target gene of interest in a standard shRNA vector or clients can choose a custom design based on their needs. All target gene constructs are cloned and verified before packaging into LentiPrep lentivirus particles. Validation of construct knockdown is also available to ensure rapid, guaranteed effect. However transcript knockdown does not always correlate with phenotypic effect (our technical scientists can guide clients through this selection process).

Similar services are provided for shRNA and CRISPR knockdown approaches. Data packets for each are available on request. 

(A) HEK293 cells (DIC) were transduced with LentiPrep particles expressing lacZ gene, and co-transduced with either LentiPrep particles containing shRNA to lacZ (lacZ), negative control lamin (lamin) gene, or mock transduced (Mock), with all vectors containing a co-expressed GFP marker (GFP) on the plasmid for transduction confirmation. (B) B-galactosidase activity assay to determine extent of shRNA knockdown of lacZ expression in cells from panel (A). B-galactosidase activity was normalized to control cells containing lacZ transduction alone, while shRNA co-transduced cells showed decreased lacZ expression depending on the gene targeted. This is in contrast to control cells with no lacZ expression which show no significant level of activity (n=3-5 experiments per treatment). (C) Western blot for lamin (shRNA knockdown) or actin (control, empty shRNA vector) proteins after stable transduction and expression of shRNA LentiPrep contructs. Each cell population (#1-5, bottom) were tested for lamin (lam) and lacZ (lac) expression, and all showed significant knockdown of lamin proteins (antibody recognizes lamins A/C as two separate sized bands at 68-78kD). Marker (M) shown on left side with sized bands.

(A) HEK293 cells (DIC) were transduced with LentiPrep particles expressing lacZ gene, and co-transduced with either LentiPrep particles containing shRNA to lacZ (lacZ), negative control lamin (lamin) gene, or mock transduced (Mock), with all vectors containing a co-expressed GFP marker (GFP) on the plasmid for transduction confirmation. (B) B-galactosidase activity assay to determine extent of shRNA knockdown of lacZ expression in cells from panel (A). B-galactosidase activity was normalized to control cells containing lacZ transduction alone, while shRNA co-transduced cells showed decreased lacZ expression depending on the gene targeted. This is in contrast to control cells with no lacZ expression which show no significant level of activity (n=3-5 experiments per treatment). (C) Western blot for lamin (shRNA knockdown) or actin (control, empty shRNA vector) proteins after stable transduction and expression of shRNA LentiPrep contructs. Each cell population (#1-5, bottom) were tested for lamin (lam) and lacZ (lac) expression, and all showed significant knockdown of lamin proteins (antibody recognizes lamins A/C as two separate sized bands at 68-78kD). Marker (M) shown on left side with sized bands.

Lentiviral Transduction in Primary Neurons

LentiPrep targeted shRNA against Tau can efficiently knockdown Tau protein (red) after 72 hours. DAPI stained nuclei (blue) identify cell numbers after 6 DIV.